Showing results (31-40 of 196) with videos related to
Sort By:
Pageof 20
Food and Drug Law Journal|February 11, 2014
Excavating treasure from the amber of the prior art: why the public benefit doctrine is ill-suited to the pharmaceutical sciencesRobert Alan HessFood and Drug Law Journal|February 11, 2014
Oversight overhaul: eliminating the premarket review of medical devices and implementing a provider-centered postmarket surveillance strategyBonnie ScottFood and Drug Law Journal|August 10, 2004
A brief history of 180-day exclusivity under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic ActErika King LietzanFood and Drug Law Journal|April 26, 2018
FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness EvidenceFrank J Sasinowski, Alexander J VarondFood and Drug Law Journal|March 15, 2014
Accounting for heterogeneous treatment effects in the FDA approval processAnup Malani, Oliver Bembom, Mark van der LaanFood and Drug Law Journal|March 15, 2014
Food after Fukushima--Japan's regulatory response to the radioactive contamination of its food chainGijs Berends, Megumi KobayashiFood and Drug Law Journal|March 20, 2014
Credible deterrence: FDA and the Park Doctrine in the 21st centuryPatrick O'LearyFood and Drug Law Journal|March 20, 2014
Does Sackett foreshadow the end of non-reviewability for FDA warning letters?Katelyn DeRuyterFood and Drug Law Journal|March 20, 2014
Direct-to-consumer genetic testing: learning from the past and looking toward the futureStephanie BairPageof 20